Philips highlights coronary contrast reduction study results

2021 11 30 16 08 9693 Philips Rsna 2021 400

Philips Healthcare parent Royal Philips is highlighting data from the Dynamic Coronary Roadmap for Contrast Reduction (DCR4Contrast) trial presented at the European Association of Percutaneous Cardiovascular Interventions (EuroPCR) 2023 course.

The trial assessed whether the company's Dynamic Coronary Roadmap can reduce volumes of iodinated contrast media administered during percutaneous coronary intervention (PCI) procedures. It ran from November 2019 to February 2023.

The roadmap is a real-time visualization software that eliminates the need for more contrast media injections, according to Philips. It does so by overlaying the angiogram onto real-time motion-compensated 2D fluoroscopic imaging, which gives interventionalists continuous visual feedback on the positioning of guide wires and catheters.

The company said the study found that the roadmap reduced the total iodine contrast volume per procedure on average by 28.8%. It also reduced the number of angiograms per procedure on average by three runs based on a procedure with an average of 11 runs or 26.3% reduction.

The results will also be presented May 18 at the Society for Cardiovascular Angiography and Interventions (SCAI) 2023 scientific sessions being held in Phoenix, AZ.

Page 1 of 3578
Next Page